News room

Egetis is an innovative and integrated pharmaceutical company, focusing on projects in late-stage development for commercialization for treatments of serious diseases with significant unmet medical needs in the orphan drug segment

Change in the number of shares and votes in Egetis Therapeutics

January 31, 2023

Stockholm, Sweden, January 31, 2023. The number of shares and votes in Egetis Therapeutics AB (publ) (“Egetis” or the “Company”) (STO: EGTX) has increased in the month of January as a result of the directed issue of shares announced on 25 January 2023.
The total number of shares and votes has increased by 35,000,000, from 214,589,128 to 249,589,128. The share capital has increased by approximately SEK 1,842,106, from approximately SEK 11,294,169 to approximately SEK 13,136,275.



Contact us

Address: Klara Norra Kyrkogata 26, SE 111 22 Stockholm, Sweden

Phone: +46 8 679 72 10